Biotech billionaire Dietmar Hopp digs deeper to back one of the drug developers in his portfolio
Biotech billionaire Dietmar Hopp is opening up the cash vault to help out one of his biotech startups.
Operating through dievini Hopp BioTech holding, Hopp has sunk a little more than $40 million into Heidelberg Pharma. The money can be put to use on the Phase I/II clinical program for their lead drug: HDP-101, a BCMA ATAC for multiple myeloma. HDP-102, a CD37 ATAC for non-Hodgkin’s lymphoma, and HDP-103, a PSMA ATAC for metastatic castration-resistant prostate cancer, are in preclinical testing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.